Mounjaro 15 mg Injection Pen

Description

Mounjaro 15 mg injection pen is a once-weekly injectable GLP-1 and GIP receptor agonist, delivering the highest therapeutic dose of tirzepatide. It’s designed for adults with type 2 diabetes or obesity who require maximum metabolic control and advanced support for weight loss.

As the final step in the Mounjaro dosage progression, this pen is recommended only for patients who have safely completed lower doses (2.5 → 5 → 7.5 → 10 → 12.5 mg).

Key Features:

• Dual GLP-1 + GIP action for superior glucose and weight management

• Contains 15 mg tirzepatide per injection

• Once-weekly self-injection for convenience

• Clinically proven to reduce A1C and promote significant weight loss (FDA Overview)

• Ideal for advanced treatment progression

Usage Instructions:

• Inject once weekly, on the same day each week

• Can be administered in the abdomen, thigh, or upper arm

• Rotate injection sites each time

• Begin only after completing 12.5 mg dose for at least 4 weeks

• Follow your healthcare provider’s instructions carefully

Mounjaro 15 mg Injection Pen Side Effects:

May include nausea, diarrhea, vomiting, or fatigue, especially during initial dose escalation. Most side effects decrease over time. See the FDA Mounjaro Medication Guide for detailed safety information.

Storage Instructions:

• Refrigerate at 36°F–46°F (2°C–8°C)

• Keep in original packaging to protect from light

• Do not freeze